INTRODUCTION: The effects of doxorubicin/cyclophosphamide (A/C; 6 cycles) chemotherapy on bone mineral density (BMD), quantitative ultrasonography (QUS) and bone turnover markers in pre-menopausal women with oestrogen receptor-negative breast cancer (BC) were compared with age-matched controls. METHODS: Among 106 women (BC=53, controls=53), BMD (spine and hip), QUS (calcaneus and phalanges) and bone marker levels were measured at baseline, 6 and 12 months. Correlations between parameters were determined by Spearman's rho. RESULTS: All BC patients became amenorrhoeic after chemotherapy and remained so for the duration of treatment. BC patients had significant bone loss at all sites (P.005) and significant increases in bone turnover (P.05). There were significant correlations between BMD, QUS and bone markers (P.05). CONCLUSIONS: Results confirm A/C's deleterious influence on bone health in pre-menopausal women with BC and established QUS's utility for monitoring bone effects. Large-scale longitudinal studies are needed to further understand and prevent bone changes following chemotherapy.
INTRODUCTION: The effects of doxorubicin/cyclophosphamide (A/C; 6 cycles) chemotherapy on bone mineral density (BMD), quantitative ultrasonography (QUS) and bone turnover markers in pre-menopausal women with oestrogen receptor-negative breast cancer (BC) were compared with age-matched controls. METHODS: Among 106 women (BC=53, controls=53), BMD (spine and hip), QUS (calcaneus and phalanges) and bone marker levels were measured at baseline, 6 and 12 months. Correlations between parameters were determined by Spearman's rho. RESULTS: All BC patients became amenorrhoeic after chemotherapy and remained so for the duration of treatment. BC patients had significant bone loss at all sites (P.005) and significant increases in bone turnover (P.05). There were significant correlations between BMD, QUS and bone markers (P.05). CONCLUSIONS: Results confirm A/C's deleterious influence on bone health in pre-menopausal women with BC and established QUS's utility for monitoring bone effects. Large-scale longitudinal studies are needed to further understand and prevent bone changes following chemotherapy.
Authors: T Ponnapakkam; R Katikaneni; T Nichols; G Tobin; J Sakon; O Matsushita; R C Gensure Journal: J Endocrinol Invest Date: 2011-07-12 Impact factor: 4.256
Authors: Gabrielle A Langmann; Karen T Vujevich; Donna Medich; Megan E Miller; Subashan Perera; Susan L Greenspan Journal: J Clin Densitom Date: 2012-03-16 Impact factor: 2.617
Authors: Zhangting Yao; Bhavna Murali; Qihao Ren; Xianmin Luo; Douglas V Faget; Tom Cole; Biancamaria Ricci; Dinesh Thotala; Joseph Monahan; Jan M van Deursen; Darren Baker; Roberta Faccio; Julie K Schwarz; Sheila A Stewart Journal: Cancer Res Date: 2020-01-13 Impact factor: 12.701
Authors: K M Winters-Stone; J Dobek; L M Nail; J A Bennett; M C Leo; B Torgrimson-Ojerio; S-W Luoh; A Schwartz Journal: Osteoporos Int Date: 2012-09-21 Impact factor: 4.507